Carl Icahn Doubles Down on Herbalife Bet

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Carl Icahn Doubles Down on Herbalife Bet

© courtesy of Herbalife Ltd.

[cnxvideo id=”655424″ placement=”ros”]Herbalife Ltd. (NYSE: HLF) has been more than a controversial stock over the past three years or more. Short seller and activist investor Bill Ackman of Pershing Square Capital Management had roughly a $1 billion bet against this company and has been a vocal challenger, calling Herbalife a pyramid scheme. But this has not been without contest. Carl Icahn has seen Ackman’s bet and is continuing to raise the stakes.

Following the company’s most recent earnings report, shareholders were less than enthused about the stock. And as a result, shares were sent to a two-month low. The fourth-quarter results were more than enough for investors, but guidance for the first quarter was relatively weak.

Barron’s reported early on Monday that Icahn Enterprises L.P. (NASDAQ: IEP) announced it had increased its stake in Herbalife to 24.57% from its previous level of 24.18%. Although this might not seem like a big move, that chunk of stock (372,324 shares) cost roughly $19 million.

[nativounit]

The U.S. Federal Trade Commission (FTC) is allowing Icahn to acquire up to a 50% stake in Herbalife. Previously, the FTC had allowed Icahn a 35% stake, back in July 2016, when the agency abandoned its “witch hunt” against Herbalife.

At the time, Herbalife treated this as a victory over Ackman after he had released multiple videos that were meant to show the company’s practices were deceptive (or worse). Herbalife’s public posturing of the settlement is that this does not change Herbalife’s business model as a direct selling company.

Shares of Herbalife were trading up 2.4% at $53.50 on Monday, with a consensus analyst price target of $74.00 and a 52-week trading range of $47.62 to $72.22.

IEP was trading at $52.73. The 52-week range is $45.42 to $66.92, and the consensus price target is $50.50.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618